Antitumor immune responses are mediated primarily by T cells1. Downregulation of the
major histocompatiblity complex (MHC) and the molecules that costimulate the immune …

Bispecific antibodies are of great interest due to their ability to simultaneously bind and
engage different antigens or epitopes. Nevertheless, it remains a challenge to assemble …

4–1BB ligand (4–1BBL), a member of the tumor necrosis factor (TNF) superfamily, interacts
with 4–1BB (CDw137) expressed on activated T cells and delivers a costimulatory signal for …

CD30, the so-called Reed–Sternberg antigen, constitutes a promising cell-specific target for
the treatment of Hodgkin's lymphoma. Starting from the previously characterized cognate …

The concept of antibody-mediated targeting of antigenic MHC/peptide complexes on tumor
cells in order to sensitize them to T-lymphocyte cytotoxicity represents an attractive new …

To overcome dose limiting toxicities and to increase efficacy of immunotherapy of cancer, a
number of strategies are under development for selectively redirecting effector …

The cure of human Hodgkin's tumors heterotransplanted into SCID mice can be achieved by
two bispecific monoclonal antibodies (Bi‐mAb) directed against the tumor‐associated CD30 …

Fifteen patients with refractory Hodgkin's disease were treated in a phase I/II dose escalation
trial with the NK-cell activating bispecific monoclonal antibody HRS-3/A9 which is directed …

The human high-affinity IgG receptor, hFcγRI (CD64), is exclusively expressed on myeloid
cells, where it serves an important role as a (cytotoxic) trigger molecule. To establish an in …

As demonstrated in several preclinical models, bispecific Abs are attractive
immunotherapeutic agents for tumor treatment. We have previously reported that a …